We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Rocket Pharmaceuticals
RCKT
$424M
| $1.53M | ﹤0.01% |
624,303
+209,806
| +51% | +$1.06M |
|
1002
Tenet Healthcare
THC
$21.5B
| $1.53M | ﹤0.01% |
8,671
-21,215
| -71% | -$3.19M |
|
1003
Synaptics
SYNA
$3.72B
| $1.51M | ﹤0.01% |
23,352
+1,939
| +9% | +$114K |
|
|
FLCG
1004
Federated Hermes MDT Large Cap Growth ETF
FLCG
$610M
| $1.51M | ﹤0.01% |
50,004
-50,000
| -50% | -$1.36M |
|
1005
EXL Service
EXLS
$5.82B
| $1.51M | ﹤0.01% |
34,441
-365
| -1% | -$16.7K |
|
1006
PROG Holdings
PRG
$1.56B
| $1.5M | ﹤0.01% |
51,263
-7,200
| -12% | -$200K |
|
1007
Carlisle Companies
CSL
$14.2B
| $1.5M | ﹤0.01% |
4,029
-370
| -8% | -$137K |
|
1008
Saic
SAIC
$5.33B
| $1.5M | ﹤0.01% |
13,328
-3,558
| -21% | -$405K |
|
1009
Brink's
BCO
$4.57B
| $1.49M | ﹤0.01% |
16,676
-6,007
| -26% | -$523K |
|
1010
Vitamin Cottage Natural Grocers
NGVC
$633M
| $1.49M | ﹤0.01% |
37,929
+21,062
| +125% | +$975K |
|
1011
W.P. Carey
WPC
$16.1B
| $1.48M | ﹤0.01% |
23,709
-2,643
| -10% | -$163K |
|
1012
First Bancorp
FBNC
$2.65B
| $1.47M | ﹤0.01% |
33,397
+10,909
| +49% | +$442K |
|
1013
Pediatrix Medical
MD
$2.16B
| $1.47M | ﹤0.01% |
102,452
-61,051
| -37% | -$837K |
|
1014
RenaissanceRe
RNR
$13.7B
| $1.47M | ﹤0.01% |
6,043
+10
| +0.2% | +$2.42K |
|
1015
NMI Holdings
NMIH
$3.37B
| $1.47M | ﹤0.01% |
34,765
-1,015
| -3% | -$38.1K |
|
1016
Veracyte
VCYT
$3.48B
| $1.46M | ﹤0.01% |
54,167
-40,256
| -43% | -$1.17M |
|
1017
iShares JPMorgan EM Local Currency Bond ETF
LEMB
$723M
| $1.45M | ﹤0.01% |
+35,988
| New | +$1.4M |
|
|
SGI
1018
Somnigroup International
SGI
$13.5B
| $1.45M | ﹤0.01% |
21,311
+3,204
| +18% | +$202K |
|
1019
Agilent Technologies
A
$43.4B
| $1.45M | ﹤0.01% |
12,281
-21,945
| -64% | -$2.43M |
|
1020
Columbia Banking Systems
COLB
$8.51B
| $1.45M | ﹤0.01% |
61,944
-75,842
| -55% | -$1.76M |
|
1021
Hurco Companies Inc
HURC
$149M
| $1.45M | ﹤0.01% |
76,531
+618
| +0.8% | +$9.32K |
|
1022
CDW
CDW
$18.5B
| $1.44M | ﹤0.01% |
8,076
+3,004
| +59% | +$510K |
|
1023
Red Rock Resorts
RRR
$3.37B
| $1.43M | ﹤0.01% |
27,535
-2,975
| -10% | -$136K |
|
1024
Peapack-Gladstone Financial
PGC
$800M
| $1.43M | ﹤0.01% |
50,594
+1,676
| +3% | +$46K |
|
1025
Entegris
ENTG
$20.6B
| $1.42M | ﹤0.01% |
17,661
-153,253
| -90% | -$11.6M |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.